Ndjeka N, et al. - Through a Clinical Access Programme with strict inclusion and exclusion criteria, South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline. The patients received 24 weeks bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as required. Results demonstrate achievement of a high rate of successful treatment outcomes with bedaquiline addition to an optimised background regimen in this MDR-TB and XDR-TB cohort.